CSIMarket
 


Longeveron Inc   (LGVN)
Other Ticker:  
 

Cumulative Longeveron Inc 's Quick Ratio for Trailing Twelve Months Period

LGVN's Quick Ratio for Trailing Twelve Months Period and Cash & cash equivalent, Current Liabilities growth


Select the Comparisons : Select the Ratio:

LGVN Quick Ratio for Trailing Twelve Months Period

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Growth -8.64 % 12.82 % 49.79 % 124.27 % 164.98 %
Y / Y Cash & cash equivalent Growth - - - -43.9 % -
Quick Ratio for Trailing Twelve Months Period 2.88 2.58 2.11 1.35 2.94
Total Ranking # 757 # 901 # 1114 # 1713 # 1117
Seq. Current Liabilities Growth -16.85 % 13.55 % -26.17 % 31.06 % 2.68 %
Seq. Cash & cash equivalent Growth -54.57 % -36.7 % -30.43 % - -


Quick Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Sep 30 2023
On the trailing twelve months basis Longeveron Inc Cash & cash equivalent average remained unchanged by % in III. Quarter year on year, while Current Liabilities faded to $ 3 millions, this led to increase in in Longeveron Inc 's Quick Ratio for Trailing Twelve Months Period to 2.88, Quick Ratio for Trailing Twelve Months Period remained below Longeveron Inc average.
Quick Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 363 other companies have achieved higher Quick Ratio for Trailing Twelve Months Period than Longeveron Inc . While overall ranking remained unchanged compare to previous quarter at no. .

What is Quick Ratio?
Learn more about LGVN
Quick Ratio LGVN in the most recent quarter
Quick Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 364
Sector # 663
S&P 500 # 1279


Quick Ratio for Trailing Twelve Months Period Statistics
High Average Low
8.17 3.88 1.35
(Mar 31 2022)   (Dec 31 2022)




Companies with similar average Quick Ratio for Trailing Twelve Months Period for 12 months ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Quick Ratio for Trailing Twelve Months Period
Context Therapeutics Inc   7.89 
Painreform Ltd  7.80 
Immuron Limited  7.73 
Marinus Pharmaceuticals Inc   7.70 
Aclaris Therapeutics Inc   7.68 
Enlivex Therapeutics Ltd   7.60 
Lexicon Pharmaceuticals Inc   7.50 
Liquidia Corporation  7.43 
Capricor Therapeutics inc   7.43 
Pyxis Oncology Inc   7.40 
Aeterna Zentaris Inc   7.39 
Abcellera Biologics Inc   7.36 
Pulmatrix Inc   7.33 
Dermata Therapeutics Inc   7.30 
Glycomimetics Inc   7.22 
Rhythm Pharmaceuticals inc   7.21 
Chemomab Therapeutics Ltd   7.21 
Nektar Therapeutics  7.19 
Mirati Therapeutics Inc   7.17 
Leap Therapeutics inc   7.16 
United Therapeutics Corporation  7.10 
Tango Therapeutics Inc   7.01 
Bolt Biotherapeutics Inc   7.00 
Moleculin Biotech Inc   6.95 
Hoth Therapeutics Inc   6.91 
Zai Lab Limited  6.91 
Vera Therapeutics Inc   6.90 
Enanta Pharmaceuticals Inc  6.88 
Lexaria Bioscience Corp   6.86 
Virios Therapeutics Inc   6.83 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com